Muscle & Brawn 2.0 is live! New Tools, Voice Reader, Compound Index, Features and more on the way. Want to explore what’s new → Click Here
Independent & reader-supported — every article medically reviewed

Peptides / GHRPs and ghrelin agonists

116 In the index

Relamorelin RELA

An experimental medication studied in large human trials for a stomach-emptying disorder common in diabetes. Results have been mixed, with some studies falling short of their goals, and it remains unapproved.

Also known as RM-131

Effects Build muscle
Routes Subcutaneous
Legal status Unapproved / investigational
WADA Banned at all times

Molecular Structure of C43H50N8O5S

Drag to rotate · scroll to zoom

  • Carbon
  • Hydrogen
  • Nitrogen
  • Oxygen
  • Sulfur

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula
C43H50N8O5S
Molar mass
791.0
CAS
661472-41-9
PubChem CID
44251769

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not yet approved; investigational
Reported range Phase II/III trial doses: 10-100 mcg subcutaneous, once or twice daily
Route Subcutaneous injection
Frequency Once or twice daily (trial protocol)
Duration Trial durations of several weeks to months

An investigational ghrelin receptor agonist studied for diabetic gastroparesis; mixed trial results have delayed approval, and it is not currently an approved product.

Where this comes from Published Phase II/III clinical trial data

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.